Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Moderna, Inc. has announced. , a biotech company that is a leading biotech company in mRNA therapies and vaccines, today announced that the first participant underwent doses in a phase 1 study of mRNA-1189, the company’s Epstein-Barr virus (EBV) vaccine candidate. The study is known as an eclipse. “EBV is one of the most common … Read more